Navigation Links
The Oclaro Next-Generation Orion Fiber-Coupled Diode Laser Raises the Bar for Performance, Cost and Reliability for Solid State Lasers

SAN JOSE, Calif., Jan. 12 /PRNewswire-FirstCall/ -- Oclaro, Inc. (Nasdaq: OCLR), a provider of optical components for industrial applications, today unveiled the industry's lowest price / highest performance 8xx nm fiber-coupled laser diode and will be showcasing the new Orion™ platform at Photonics West in San Francisco, Calif.  The latest Orion fiber-coupled diode laser is one-half the size and 1.5x the brightness of competitive products in its category and delivers 30W of power at 808nm and 35W of power at 880nm wavelengths, with 95% of the light contained within a 0.15NA from a 200um core diameter fiber.

"Until now, there has been no product to effectively serve the mid-power fiber-coupled market with the right level of brightness, low cost, robustness and reliability," said Scott Dunbar, General Manager of High Power Laser Diode Portfolio for Oclaro.  "The Orion platform is designed to meet all of these needs and allows DPSSL systems to maintain their competitive edge against fiber laser systems."

The latest Orion platform is the first integrated product resulting from Oclaro's acquisition of Newport Spectra-Physics high power laser diodes business.  By combining the cutting-edge technologies in device design and proprietary E2 facet passivation from Oclaro's Zurich facility with the advanced packaging technologies from Oclaro's Tucson facility, the high-brightness Orion platform delivers unmatched performance and reliability.

About the Newest Orion Platform

The Orion platform serves as the ideal solution for the DPSS laser, direct diode medical and industrial materials processing applications that demand higher power and brightness, lower cost and smaller form factors.

  • The breakthrough form-factor design allows customers to design smaller solid state lasers at lower cost and with more functionality.
  • Features advanced hermetic packaging, which greatly improves the robustness and reliability of the package.
  • Delivers 2X output power over the previous Orion family product with 30W at 808nm and 35W at 880 nm from a 200 um fiber.
  • Takes advantage of the state-of-the art 'mini-bar' design of the Orion platform to produce unparalleled brightness of >1.5mW/cm2*sr, facilitating new architectures and easier system tolerances.

With the release of the latest Orion fiber-coupled diode laser, Oclaro now offers two next generation product platforms to serve the entire mid-power fiber-coupled market segment.  The Orion platform offers the perfect solution for the sub-40W market, while the Prosario™ platform addresses the 40W+ market, resulting in the most extensive product offering of high brightness, fiber-coupled diodes in the industry today.

About Oclaro

Oclaro, Inc., with headquarters in San Jose, Calif., is a tier-one provider of high-performance optical components, modules and subsystems to the telecommunications market, and is one of the largest providers to metro and long-haul network applications. The company, formed on April 27, 2009 following the combination of Bookham, Inc. and Avanex Corporation, leverages proprietary core technologies and vertically integrated product development to provide its customers with cost-effective and innovative optical devices, modules and subsystems.  Oclaro serves a broad customer base, combining in-house and outsourced manufacturing to maximize flexibility and drive improved gross margin. Its photonic technologies also serve selected high-growth markets, including industrial, defense, life sciences, medical and scientific, with diversification providing both significant revenue streams and strategic technological advantage.  The company also provides a complete family of wavelength selective switches (WSS) capable of powering reconfigurable optical add/drop multiplexer (ROADM) applications over the entire optical network, from the edge to the core.

Oclaro is a global company, with cutting-edge chip fabrication facilities in the U.K., Switzerland and Italy, and in Tucson, Ariz. during the transition of related activities to Europe, and manufacturing sites in the U.S., Thailand and China.

Copyright 2010. All rights reserved. Oclaro, the Oclaro logo, Orion, Prosario and certain other Oclaro trademarks and logos are trademarks and/or registered trademarks of Oclaro, Inc. or its subsidiaries in the US and other countries. All other trademarks are the property of their respective owners. Information in this product release is subject to change without notice.

Editor Notes:

  1. Photonics West will take place January 23-28, 2010, in San Francisco, Calif.
  2. Oclaro will be exhibiting at the Photonics West exhibition at booth #1101
  3. To arrange an interview with representatives of Oclaro before or during the show, please contact Erika Powelson at +1 (408) 332-5877 or

SOURCE Oclaro, Inc.



SOURCE Oclaro, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Abbott and AstraZeneca Announce Selection of Next-Generation Fenofibrate ABT-335 and CRESTOR(R) Fixed-Dose Combination
2. Boston Scientifics Next-Generation Stent Shows Improved Clinical Outcomes in Complex Lesions
3. Trubion Initiates Phase 1/2 Study of TRU-016 in CLL, Announces Next-Generation Product Candidate for RA and Provides Product Pipeline Update
4. Echo Therapeutics Announces Positive Results with the Prelude(TM) SkinPrep System, the Next-Generation Skin Permeation Medium for its Symphony(TM) Transdermal Continuous Glucose Monitoring System
5. Taxus Atlas Studies Reinforce Safety and Efficacy of Boston Scientifics Next-Generation Taxus Liberte Stent
6. Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C
7. Boston Scientific Begins Clinical Trial for Next-Generation Nitinol Stent to Treat Iliac Artery Disease
8. WorldHeart Signs Agreements for Next-Generation Minimally Invasive Blood Pump
9. Orion Genomics Announces the Discovery of Novel Breast Cancer Biomarkers
10. Orion Genomics Gains Exclusive Worldwide Rights to the IGF2 Gene for Colorectal Cancer Risk Testing Through Licensing Agreement With Johns Hopkins University
11. Orion Genomics Enters Discovery Collaboration and License Agreement to Advance Personalized Diagnostics
Post Your Comments:
(Date:11/25/2015)... 2015 Kitov Pharma ceuticals ... a biopharmaceutical company focused on the development of therapeutic ... today announced the closing of its previously announced underwritten ... ), each representing 20 ordinary shares of the Company, ... ADSs and warrants were issued in a fixed combination ...
(Date:11/25/2015)...  Today AVACEN Medical announced the issue of United States patent No. ... ". This patent shields the company,s AVACEN 100 dry heat therapy medical device and specific methods ... Photo - ... ... ...
(Date:11/25/2015)... , Nov. 25, 2015 USP 800 ... drug preparations (e.g. pharmacists, pharmacy technicians, nurses, physicians, ... technicians). The chapter also covers all entities which ... pharmacies, hospitals, other healthcare institutions, patient treatment clinics, ... --> --> What is ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... November 25, 2015 , ... For the first time, Vitalalert ... Organizations, One Beat ” campaign. The partnership between the two groups began in 2014 ... MAP International’s cause. , MAP International was founded in 1954 and is an international ...
(Date:11/25/2015)... ... ... On November 25, 2015, officials of Narconon Arrowhead , the drug rehabilitation ... new cutting edge recovery program that has been 50 years in the making. ... with the purpose to free addicts from the symptoms and negative behaviors of addiction. ...
(Date:11/25/2015)... ... ... Smiles by Stevens is pleased to announce the addition of Botox® for ... aware of the benefits of Botox® in the treatment of moderate facial wrinkling, few ... and pain as a result of Jaw Tension, TMJ (temporo-mandibular joint) disorder, and Bruxism ...
(Date:11/25/2015)... ... November 25, 2015 , ... In an ongoing Clinical Study conducted by an ... IL, UV Angel is evaluating the efficacy of its product and its disinfection protocol. ... 30 beds) from May 2014 through October 2015 at a 360-bed, acute-care, academic medical ...
(Date:11/25/2015)... Spring, Md (PRWEB) , ... November 25, 2015 ... ... Pulmonary Hypertension Association (PHA) announces the nation’s Periwinkle Pioneers, individuals and groups responsible ... history of this disease. The Periwinkle Pioneers, nominated by the public, will receive ...
Breaking Medicine News(10 mins):